Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives

Kannan P Naicker,Shibo Jiang,Hong Lu,Jiahong Ni,Louise Boyer-Chatenet,Lai-Xi Wang,Asim K Debnath
DOI: https://doi.org/10.1016/j.bmc.2003.11.006
IF: 3.461
2004-01-01
Bioorganic & Medicinal Chemistry
Abstract:A structure-based design approach has been used to optimize a lead HIV-1 entry inhibitor targeted to the envelope glycoprotein gp41. The docking study on this lead compound revealed important structural requirements that need to be preserved as well as structural non-requirements that could be eliminated to substantially reduce the molecular size of the lead compound. Based on the results from docking study, a limited number of analogues were designed and synthesized. This approach yielded a new analogue (compound 4) that retained the anti-HIV-1 activity with reduced molecular size approaching towards more drug-like character.
What problem does this paper attempt to address?